功能性纤维可以通过将提取或合成的纤维掺入食品中来帮助美国人增加纤维摄入量。美国食品和药物管理局最近提出,“添加”纤维必须表现出生理健康益处,比如血糖控制,作为膳食纤维列入营养成分标签。本研究的目的是评估聚葡萄糖(PDX)的作用,一种抗哺乳动物消化的水溶性葡萄糖聚合物,当添加到相对高水分(饮料)与低水分(酒吧)食品时,餐后葡萄糖浓度。这项研究被设计为两个部分,每个部分都被控制,随机化,单盲,交叉试验。共有34和19名健康受试者被要求在饮料和酒吧中食用PDX,分别。研究了PDX在饮料中的0、8、12和16g以及在棒中的0和12g。在饮用饮料/酒吧之前收集血液样品,并在之后收集3小时以评估血浆葡萄糖和胰岛素浓度的变化。12gPDX条件对两种结果都有显著影响,因为两种基质中的葡萄糖显著增加(P>0.05),而胰岛素仅以条状形式增加(P>0.05)。PDX在所有剂量和所研究的基质下都具有良好的耐受性。在提供的剂量下,PDX不会降低两种基质中的餐后葡萄糖或胰岛素;因此,数据不支持将PDX作为膳食纤维在当前拟议规则下的营养成分标签上报告,该规则使用血糖控制作为生理益处的终点.
Functional fibers can help Americans increase their fiber intake by incorporating extracted or synthesized fibers into food products. The United States Food and Drug Administration has recently proposed that \"added\" fibers must demonstrate a physiological health benefit, such as glucose control, to be included on the Nutrition Facts label as a dietary fiber. The objective of this
study was to assess the effects of polydextrose (PDX), a water-soluble glucose polymer resistant to mammalian digestion, on postprandial glucose concentrations when added to relatively high moisture (beverage) versus low moisture (bar) food products. The
study was designed as 2 parts with each being controlled, randomized, singe-blinded, cross-over trials. A total of 34 and 19 healthy subjects were asked to consume PDX in a beverage and bar, respectively. PDX was investigated at 0, 8, 12, and 16 g in the beverage and 0 and 12 g in the bar. Blood samples were collected before beverage/bar consumption and for 3 h thereafter to evaluate changes in plasma glucose and insulin concentrations. The 12 g PDX condition had significant impact on both outcomes as glucose was significantly increased in both matrices (P > 0.05) and insulin was increased in bar form only (P > 0.05). PDX was well tolerated at all dosages and matrices investigated. PDX did not lower postprandial glucose or insulin in either matrix at the doses provided; therefore, data do not support reporting PDX as a dietary fiber on the Nutrition Facts label under the current proposed rule using glycemic control as the endpoint for physiological benefit.